atai Life Sciences Announces the Launch of PsyProtix, to Develop a Precision Psychiatry Approach for Treatment-Resistant Depression (TRD)
NEW YORK, Oct. 11, 2021 (GLOBE NEWSWIRE) — atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the launch of PsyProtix, a new platform…
Duke Signed a License Agreement with Splendo Health
Duke University and Splendo Health have entered into a license agreement. The Dutch digital health startup is a collaboration between Duke University and Splendo Consulting. Splendo Health has developed SplendoFit, a comprehensive digital platform with sensors and…
ATP Announces $40 Million in Series A Funding for srRNA Therapeutics Trailblazer Replicate Bioscience
“We started Replicate to build a best-in-class srRNA platform from scratch—to pursue our vision of a better way to make srRNAs that we are convinced can solve life-threatening medical problems, from drug resistance in cancer…
Durham Startup Founded by Duke Scientists Thinks it has a Way to Improve Antidepressants
BY ZACHERY EANES The Herald Sun, August 27, 2021 For nearly a third of patients, the most common form of antidepressants on the market don’t seem to work well. But a biotech startup founded by…
Biomeme & Predigen Merge to Enable Point-of-Care Delivery of Host Response Tests That Address Critical Unmet Needs in Healthcare
Biomeme and long-time collaborator, Predigen, have entered an agreement to merge in order to expand Biomeme’s diagnostic capabilities. Combining Predigen’s extensive years of host response research with Biomeme’s gold-standard, portable real-time PCR platform, this merger…
Predictive Technology Developed at Duke Promises to Reduce Inefficiencies in Surgery
“We were able to take a Duke-born technology, foster and pilot it in the entrepreneurial environment of Duke to the point it could be translated out as a start-up, partner with Duke to bring a…
Immunomic’s Academic Collaborator Dr. John Sampson Recognized as “World Expert” in Glioblastoma as Part of Glioblastoma Awareness Day
ROCKVILLE, Md. July 21, 2021 — (BUSINESS WIRE ) — Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that its’ academic collaborator, Dr.…
Xilis Raises $70 Million Series A Financing to Advance Diagnostic and Drug Discovery and Development Platform Leveraging Proprietary MicroOrganoSphere™ Technology
Nasdaq highlights Xilis on their tower in Times Square. — Xilis’ MicroOrganoSphereTM (MOS) technology generates thousands of miniature patient- derived tumors that capture the original heterogeneity and microenvironment for therapeutic profiling. — The company’s platform…
Antibody Targets Mechanism That Enables Lung Cancer to Grow and Spread
By Sarah Avery DURHAM, N.C. – An investigational antibody in clinical trials for lung cancer appears to disrupt a mechanism that tumor cells exploit to avoid being destroyed by the body’s innate immune system, researchers…